Our top pick for
Aptinyx Inc is a biotechnology business based in the US. Aptinyx shares (APTX) are listed on the NASDAQ and all prices are listed in US Dollars. Aptinyx employs 43 staff and has a trailing 12-month revenue of around USD$3.2 million.
|52-week range||USD$1.6 - USD$5.28|
|50-day moving average||USD$3.4221|
|200-day moving average||USD$3.6201|
|Wall St. target price||USD$10.67|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.692|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$3.2 million|
|Gross profit TTM||USD$-40,661,000|
|Return on assets TTM||-28.49%|
|Return on equity TTM||-46.04%|
|Market capitalisation||USD$175.2 million|
TTM: trailing 12 months
There are currently 1.0 million Aptinyx shares held short by investors – that's known as Aptinyx's "short interest". This figure is 1.6% down from 1.1 million last month.
There are a few different ways that this level of interest in shorting Aptinyx shares can be evaluated.
Aptinyx's "short interest ratio" (SIR) is the quantity of Aptinyx shares currently shorted divided by the average quantity of Aptinyx shares traded daily (recently around 184029.60992908). Aptinyx's SIR currently stands at 5.64. In other words for every 100,000 Aptinyx shares traded daily on the market, roughly 5640 shares are currently held short.
However Aptinyx's short interest can also be evaluated against the total number of Aptinyx shares, or, against the total number of tradable Aptinyx shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aptinyx's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Aptinyx shares in existence, roughly 20 shares are currently held short) or 0.0376% of the tradable shares (for every 100,000 tradable Aptinyx shares, roughly 38 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Aptinyx.
Find out more about how you can short Aptinyx stock.
We're not expecting Aptinyx to pay a dividend over the next 12 months.
Over the last 12 months, Aptinyx's shares have ranged in value from as little as $1.6 up to $5.28. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aptinyx's is 1.2098. This would suggest that Aptinyx's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase I clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc to develop a compound for the treatment of major depressive disorder. Aptinyx Inc. was founded in 2015 and is headquartered in Evanston, Illinois.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.